Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
KERYX BIOPHARMACEUTICALS INC (KERX)
|
Add to portfolio |
|
|
|
| Price: |
$3.36
| | Metrics |
| OS: |
102.4
|
M
| |
|
|
| Market cap: |
$344
|
M
| |
-167
|
% ROIC
|
|
Net debt:
|
$106
|
M
| |
|
|
|
EV:
|
$450
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($87.6)
|
M
| |
|
|
|
EBIT
|
($88.6)
|
M
| |
|
|
| EPS |
($0.77)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| Revenues | 60.6 | 32.0 | 13.7 | 10.8 | 7.0 | 28.6 | 5.0 | 0.0 |
| Revenue growth | 89.6% | 133.8% | 26.4% | 54.6% | -75.5% | 471.6% | | -100.0% |
| Cost of goods sold | 25.0 | 40.7 | 6.6 | 0.5 | 0.0 | 0.0 | -65.4 | -40.0 |
| Gross profit | 35.6 | -8.7 | 7.0 | 10.3 | 7.0 | 28.6 | 70.4 | 40.0 |
| Gross margin | 58.7% | -27.2% | 51.4% | 95.4% | 100.0% | 100.0% | 1408.1% | |
| Selling, general and administrative | 99.6 | 84.6 | 81.4 | 70.1 | 19.3 | 7.0 | 12.2 | 11.3 |
| Research and development | 37.7 | 29.5 | 36.7 | 51.5 | 34.7 | 20.0 | 53.2 | 28.7 |
| General and administrative | | | | | | | 6.7 | 6.3 |
| EBIT | -101.7 | -122.8 | -111.1 | -111.2 | -47.1 | -25.6 | -28.7 | -21.2 |
| EBIT margin | -167.7% | -383.8% | -811.9% | -1027.5% | -672.6% | -89.5% | -575.0% | |
| Pre-tax income | -163.7 | -161.0 | -123.1 | -110.8 | -46.7 | -25.4 | -28.4 | -20.5 |
| Income taxes | -0.2 | 0.1 | 0.1 | 0.7 | 0.0 | -2.6 | -0.2 | -7.2 |
| Tax rate | 0.1% | | | | 0.0% | 10.4% | 0.9% | 35.0% |
| Earnings from continuing ops | -163.4 | -161.1 | -123.1 | -111.5 | -46.7 | -22.7 | -28.4 | -20.5 |
| Earnings from discontinued ops | | | | | | | 0.2 | 0.1 |
| Net income | -163.4 | -161.1 | -123.1 | -111.5 | -46.7 | -22.7 | -28.1 | -20.3 |
| Net margin | -269.5% | -503.7% | -900.2% | -1030.2% | -667.6% | -79.5% | -562.5% | |
| |
| Diluted EPS | ($1.43) | ($1.52) | ($1.19) | ($1.23) | ($0.58) | ($0.32) | ($0.42) | ($0.35) |
| Shares outstanding (diluted) | 114.5 | 105.8 | 103.9 | 91.0 | 81.0 | 71.6 | 67.4 | 59.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|